Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (the "Company") on February 5, 2019, covering events occurring on December 11, 2018, and January 30, 2019. The filing details a strategic restructuring involving the Company's previously wholly-owned subsidiary, Melt Pharmaceuticals, Inc. ("Melt"), focusing on the spin-off of specific pharmaceutical assets and a subsequent capital raise by the subsidiary.
Key Financial Metrics and Transactions
- Asset Transfer: On December 11, 2018, the Company transferred intellectual property and rights for conscious sedation and analgesia formulations to Melt.
- Royalty Obligation: Melt is required to pay the Company royalties of up to 8% of net sales of the transferred products while patent rights remain outstanding.
- Capital Raise: On January 30, 2019, Melt closed a Series A Preferred Stock round raising approximately $11,000,000 at a price of $5.00 per share.
- Ownership Structure: Following the Series A round, Harrow Health, Inc. retains 3,500,000 shares of Melt common stock, representing approximately 44% of Melt's equity and voting interests.
Material Changes and Corporate Actions
The primary material change is the divestiture of specific product lines to a subsidiary that is now partially independent. While the Company previously owned Melt wholly, the Series A financing diluted Harrow's ownership to 44%. Additionally, the Company's CEO, Mark L. Baum, and CFO, Andrew R. Boll, serve as directors of Melt and entered into consulting agreements with the subsidiary on May 1, 2018.
Outlook, Risks, and Contingencies
- Future IPO: Melt has agreed to use commercially reasonable efforts to file a registration statement on Form S-1 for an initial public offering (IPO) by September 30, 2020.
- Related Party Transactions: The involvement of Harrow's executive leadership in Melt's board and consulting roles presents related party transaction considerations.
- Financial Impact: The filing does not provide specific revenue, profit, or cash flow figures for Harrow Health, Inc. for the reporting period, as this is a current report on specific events rather than a periodic financial statement.
Key Facts for Investor Verification
- Verify the full text of the Asset Purchase Agreement (Exhibit 10.1) to understand specific conditions beyond the 8% royalty cap.
- Confirm the exact dilution impact on Harrow's consolidated financial statements resulting from the loss of majority control in Melt.
- Monitor Melt's progress toward the September 30, 2020, deadline for filing its Form S-1 registration statement.
- Review the consulting agreements between Harrow executives and Melt for potential conflicts of interest or additional compensation arrangements.